XSHG
603998
Market cap676mUSD
Oct 09, Last price
10.63CNY
1D
3.10%
1Q
14.42%
Jan 2017
-39.67%
IPO
76.29%
Name
Hunan Fangsheng Pharmaceutical Co Ltd
Chart & performance
P/E
15.23
P/S
2.67
EPS
0.70
Div yield, %
3.98%
Shrs. gr., 5y
0.58%
Rev. gr., 5y
6.43%
Revenues
1.75b
-1.75%
Net income
306m
+20.05%
CFO
385m
+97.30%
Dividend
Sep 11, 20260.2 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Operating within China, Hunan Fangsheng Pharmaceutical Co., Ltd. is engaged in the complete spectrum of pharmaceutical activities, from research and development to manufacturing and sales. Its diverse product line encompasses tablets, capsules, and granules, addressing a wide array of therapeutic areas such as cardiovascular, cerebrovascular, orthopedic, pediatric, gynecological, traumatology, and anti-infective conditions. The company was established in 2002 and is headquartered in Changsha, China.
Key people
Wei'en Zhou
Deputy General Manager · since 2015
Bo Chen
Deputy General Manager, Director · since 2015
Yuan Ming Tan
Vice Chairman of the Board · since 2015
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||